Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age

INTRODUCTION: This ongoing, prospective, open-label, non-comparative, multicenter phase IV study is evaluating the safety and efficacy of recombinant human growth hormone (rhGH; Omnitrope(®), Sandoz GmbH) in short children born small for gestational age (SGA). Here we report data from patients who h...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Hans-Peter, Walczak, Mieczysław, Birkholz-Walerzak, Dorota, Szalecki, Mieczyslaw, Nanu, Michaela, Woehling, Heike, Schuck, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833801/
https://www.ncbi.nlm.nih.gov/pubmed/26886776
http://dx.doi.org/10.1007/s12325-016-0301-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833801/
https://www.ncbi.nlm.nih.gov/pubmed/26886776
http://dx.doi.org/10.1007/s12325-016-0301-1

Ejemplares similares